

**FORMULATION, DEVELOPMENT AND EVALUATION OF FUROSEMIDE AND
AMLODIPINE ORODISPERSIBLE TABLETS DRUG DELIVERY SYSTEMS**

Mahmoud Mahyoob Alburyhi^{1*}, Yahya Abduh Salim Mohamed², Abdalwali Ahmed Saif¹, Maged Alwan Noman¹, Jalal H. Abdullah³ and Tawfeek AA. Yahya³

¹Professor Dr. of Pharmaceutics and Industrial Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.

²Associate Professor Dr. of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.

³Professor Dr. of Medicinal Chemistry and Drug Design, Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.



*Corresponding Author: Prof. Dr. Mahmoud Mahyoob Alburyhi

Professor Dr. of Pharmaceutics and Industrial Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.

Article Received on 21/03/2025

Article Revised on 11/04/2025

Article Accepted on 01/05/2025

ABSTRACT

The objective of the present study was to prepare Furosemide and Amlodipine as Orodispersible tablets drug delivery systems. Orodispersible tablets dissolve rapidly and show higher bioavailability than conventional tablets. Furosemide and Amlodipine was selected as a model for preparation of Orodispersible Tablets by direct compression technique. Amlodipine is a long-acting calcium channel blocker (dihydropyridine) used as an anti-hypertensive and in the treatment of angina. Amlodipine is one of the calcium channel blockers that works primarily on arterial muscle and it acts by relaxing smooth muscle in the arterial wall, decreasing peripheral resistance and hence reducing blood pressure; in angina it increases blood flow to the heart muscle. Furosemide is a loop diuretic commonly used in adults, infants and children for the treatment of edematous states associated with congestive heart failure, cirrhosis of the liver and renal disease. Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents; however, they are slow to produce the desirable effect. Therefore, to decrease the patient time in suffering of these symptoms, Orodispersible drug-delivery system significantly increased patient acceptance by virtue of rapid disintegration, self-administration without water and finally improved patient compliance. Tablets were prepared by direct compression method using crospovidone and sodium starch glycolate as superdisintegrants. The tablets were evaluated for weight variation, thickness, diameter, hardness, friability, time, *in-vitro* disintegration time, assay HPLC method and *in-vitro* dissolution study. Hardness and friability data indicated good mechanical strength of tablets. The results of *in-vitro* disintegration time of F4 and F2 was found to be 9 and 2 seconds and the drug release 90.72% and 76.51% at 5 minutes respectively indicated that the tablets dispersed rapidly in the mouth. It was concluded that F4 and F2 are the best formulations of Furosemide and Amlodipine Orodispersible Tablets ODTs drug delivery systems in order to increase onset of action and bioavailability of drug.

KEYWORDS: Furosemide, Amlodipine, Orodispersible tablets, Superdisintegrants, Drug delivery systems.

INTRODUCTION**Oral drug delivery systems^[1-150]**

Most of the oral pharmaceutical dosage forms like conventional tablets and capsules are formulated to be swallowed or chewed. Elderly people and children sometimes have difficulties in swallowing these dosage forms. Such problem is more serious for bedridden patients. This problem is also applicable to active working or travelling people who do not have ready access to water. Recent advances in novel drug delivery system aims to provide rational drug therapy by enhanced safety and efficacy of drug molecule by

formulating a convenient dosage form for administration and also by ensuring better patient compliance.

Oral drug delivery has been known as the most widely used route of drug administration when compared to all the other routes that have been explored for delivery of different dosage forms to systemic circulation. The reason for such popularity of oral route may be attributed to its ease of administration. Recent advances in novel drug delivery systems (NDDS) aim at formulating a convenient dosage form for administration and to

achieve better patient compliance to enhance safety and efficacy of drug molecules.

An oral fast dissolving drug delivery system is a novel tablet dosage form, which dissolves or disintegrates in the oral cavity with a good taste and flavor increasing the acceptability of bitter drugs without the need of water or chewing and hence called melt in mouth tablets or Orodispersible or rapid disintegrating or quick dissolving tablets. The drugs may be absorbed from mouth, pharynx or esophagus while the saliva passes down into stomach. Advantages of the fast-dissolving tablets include rapid onset of action, ease of swallowing without the aid of water, enhanced dissolution rate, increased gastric absorption, minimized first pass metabolism, improved oral bioavailability and improved patient compliance. ODTs formulation combines the advantages of both conventional tablets and liquid formulations.

Solid dosage forms are popular because of low cost, ease of administration, accurate dosage self-medication, pain avoidance, and the most importantly the patient compliance. The most prevalent solid dosage forms are being tablets and capsules. One essential downside of such dosage forms is Dysphagia (Trouble in gulping) is basic among all age gatherings. Normal grumblings about the trouble in gulping tablets are size, surface, and taste of tablets. Geriatric and pediatric patients and voyaging patients, who might not have prepared access to water, are most needing simple gulping dosage forms. To satisfy these medicinal needs, pharmaceutical technologists have built up a novel oral dosage form known as Orodispersible tablets (ODTs) which disintegrate quickly in salivation, normally inside only seconds, without the need to take water.

Through the few Ten years, there has been a strong request for more rapid, patient-friendly and convenient dosage forms of drug. Though, oral routes of drug administration have got the widest acceptance comparing to the other routs of administration. Moreover, improved patient compliance is demanded in this modern era. Therefore, demand for the new technologies is also increasing. To develop a chemical entity, there is need of lot of money, hard work and sufficient time. So, focus is rather being laid on the development of new drug delivery systems for already existing medication, with enhanced efficacy and bioavailability, thus reducing the dose and dosing frequency to minimize the side effects. It is always the desire of a scientist or a dosage form designer to augment the safety of a drug molecule while maintaining its therapeutic efficacy. Recent advances in Novel Drug Delivery Systems (NDDS) wish for the same by formulating a dosage form, which is easy to be administered so as to achieve better patient compliance. For most therapeutic agents used to produce systemic effects, the oral route still represents the preferred way of drug administration, owing to its several advantages and high patient compliance compared to many other routes.

However, patients especially elder ones find tablets and capsules are difficult to be swallowing. It is estimated that 35% of the population is affected by this problem which results in a high incidence of non-compliance and ineffective therapy. The difficulty is experienced in particular by pediatric and geriatric patients, but it also applies to people who are ill in bed and to those active working patients who are busy or traveling, especially those who have no access to water and also in following conditions like: Parkinsonism, Motion sickness, Unconsciousness and Mentally disabled persons. Accordingly, to fulfil these medical needs the pharmaceutical technologists have developed a novel type of dosage form for oral administration, the Orodispersible (ODTs), tablets that disintegrate and dissolve rapidly in saliva without water. Sufficiently high aqueous solubility is crucial for their success, however. This requirement becomes increasingly problematic with the increasing number of poorly water-soluble drugs emerging onto the market.

hypertension is an important problem that requires chronic treatment. Angiotensin-converting enzyme (ACE) inhibitors were primarily considered as antihypertensive drugs which are able to reduce significantly high blood pressures in hypertensive patients. Calcium channel blockers were initially considered for treatment of angina pectoris and for the treatment of vasospastic angina. These drugs are able to markedly reduce vascular resistance and for that reason they were extensively studied in the field of hypertension. ACE inhibitors and calcium channel blocker drugs are widely used for the treatment of many cardiovascular conditions including mild to moderate hypertension and heart failure, either alone or in combination with other drugs.

The main purpose of this study was to formulate and develop an ODTs of a combined product. To produce a drug of rapid onset of action with relative disintegration time, to improve bioavailability, increase absorption and enhancing dissolution rate, to formulate a dosage form that can be used ODTs in emergency to reduce hypertension and maintains diuretic effect, to increase safety by diminishing the difficulties of swallowing, risk of choking or suffocation, to reduce drug multiple intakes, to serve in reducing economical cost issue and exploit the chances for better efficacy and prevent development of drug resistance.

Furosemide [4-chloro-N-furfuryl-5-sulphamoylanthranilic acid], is a loop diuretic commonly used in adults, infants and children for the treatment of edematous states associated with congestive heart failure, cirrhosis of the liver and renal disease. Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Amlodipine (as besylate, mesylate or maleate) [(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl) - 6-methyl - 1,4 - dihydropyridine -3 ,5-dicarboxylate], is a long-acting calcium channel blocker (dihydropyridine) used as an anti-hypertensive and in the treatment of angina. Amlodipine is one of the calcium channel blockers that works primarily on arterial muscle and it acts by relaxing smooth muscle in the arterial wall, decreasing peripheral resistance and hence reducing blood pressure; in angina it increases blood flow to the heart muscle.

The oral route of drug administration is the most important method of administering drugs for systemic effects. Of drugs that are administered orally, solid oral dosage form represents the preferred class of products. Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. These dosage forms contain a quantity of drug which is given as a single unit and they are known as solid unit dosage forms. Tablets represent unit dosage form in which one usual dose of the drug has been accurately placed. Tablets may be defined as solid pharmaceutical dosage forms containing drug substance with or without suitable diluents and have been traditionally prepared either by compression or molding methods. Frequently, tablets are discoid in shape; they are also round, oval, oblong, cylindrical or triangular. They differ greatly in size and

weight depending on the amount of drug substance present and intended method of administration. Tablets are obtained by compression of uniform volumes of powders or granules by applying high pressure and using punches and dies. The particles to be compressed consist of one or more medicaments, with or without auxiliary substance such as diluents, binders, and disintegration agents, lubricant, glide ants and substances capable of modifying the behavior of the medicaments in the digestive tracts. Such substances must be innocuous and therapeutically inert in the quantities present.

The aim of the present study was to investigate the use of superdisintegrant to formulation, development and evaluation of Furosemide and Amlodipine besylate ODTs with the intended application as ODTs.

MATERIALS AND METHODS

Furosemide and Amlodipine Besylate were obtained as a gift from (Biopharm Pharmaceutical Industry Company-Yemen). While Crospovidone, Microcrystalline Cellulose, Sodium Starch Glycolate, Magnesium Stearate, Sodium Lauryl Sulfate (SLS), Aspartame and other materials were obtained as a gift from (Shaphaco Pharmaceutical Industry Company-Yemen).

The equipment's used as shown in Table 1.

Table 1: The Equipment's Used.

No	Equipment's
1	Fourier Transform Infrared Spectrophotometer (IR. Thermoscientific Nicolet is 10)
2	UV/VIS Spectrophotometer (uv jasco 2016) No: Qc. cp-057
3	pH Meter HI 2216 pH/ ORP/ISE Meter
4	Ultra-sonic
5	Electronic Balance Sartorius No: Qc-Cp, 059
6	Hardness Tester Rimek- India. No: cp.010.
7	Disintegration Tester (disintegration tester -bj-3)
8	HPLC 2020
9	Dissolution Tester (Rc- 80C) No: Qc-cp-071
10	Tablet Machine Rotary tablets press machine Zp-7
11	Friability Tester (Cjy-300D Tablets friability tester)
12	Thickness Tester Vernier (Stainless hardened)
13	Oven (Incubator) Accelerate Stability Study Champer

Formulation and Evaluation of Furosemide and Amlodipine Formulations ODTs^[50-190]

Preparation of Furosemide and Amlodipine Formulations ODTs

Formulations (F1-F6) each tablet containing 20 mg Furosemide and 5 mg Amlodipine were prepared by direct compression method using the ingredients as shown in Table 1. Six formulations were prepared using pure drug Furosemide and Amlodipine and two superdisintegrants namely crospovidone and sodium starch glycolate. Mixing was done by using geometric mixing, in where all excipients accurately weighed then all of them except magnesium stearate were blended with

specified quantity of Furosemide and Amlodipine for 15 minutes, whereas the other excipients were blended for 5 minutes and added to the former excipients. Then all formulations were passed through sieve # 18 for particle size uniformity. This method of ordering mixing of excipients with Furosemide and Amlodipine in first six formulations. Then each mixture has compressed directly into tablets using rotary tablet compression machine of punch size 6.25mm (7mm) to prepare tablets each weighing 150mg after testing powder properties that will be shown in Preformulation tests in early research as shown in Table 2.

Table 2: Composition of Furosemide and Amlodipine Formulations ODTs.

Ingredients	Quantity per tablet					
	Formulation code					
	F1	F2	F3	F4	F5	F6
Amlodipine	5	5	5	5	5	5
Furosemide	20	20	20	20	20	20
Microcrystalline Cellulose	110.4	111	110	111	110	110.4
Sodium Starch Glycolate				8	9	8.5
Crospovidone	8.6	9	8			
Magnesium Stearate	1.5	1.5	1.5	1.5	1.5	1.5
Sodium Lauryl Sulfate SLS	1.5	1.5	1.5	1.5	1.5	1.5
Aspartame	3	3	3	3	3	3

Evaluation of Furosemide and Amlodipine orodispersible tablets

Weight variation

The weight variation test would be satisfactory method of determining the drug content uniformity. Twenty tablets randomly were taken from each batch and weighted individually, calculating the average weight, and comparing the individual tablet weights to the average. The average weight of one tablet was calculated.

Diameter test

The diameter test one of tests which used for determination of the tablets size, it is done by taking five tablets from each batch randomly. Diameter may obtain by using suitable micrometer.

Thickness test

The thickness test of five tablets were picked from each batch randomly and thickness was measured individually using "Vernier- caliper" (Electronic Digital Caliper). It is expressed in millimeter and average was calculated.

Hardness test

The hardness test or tablet crushing strength. The force required to break a tablet in a diametric compression was measured using digital tablet hardness tester. It is expressed in kg/cm². Five tablets were randomly selected from each batch and hardness of tablets was determined by using digital hardness tester. The mean values and standard deviation for each batch were calculated.

Friability test

The friability test is performed to assess the effect of friction and shocks, which may often cause tablet to chip, cap or break. Roche friabilator was used for the purpose. Pre-weighed sample of five tablets from each batch were placed in the friabilator, which was then operated for 100 revolutions. After 100 revolutions the tablets were dusted and reweighed. Compressed tablets should not lose more than 1% of their weighed.

In-vitro disintegration time

The *in-vitro* disintegration time was determined using disintegration test apparatus. A tablet was placed in each of the six tubes of the apparatus and one disc was added to each tube. The time in seconds taken for complete disintegration of the tablet with no palatable mass remaining in the apparatus was measured in seconds.

Assay of Furosemide and Amlodipine ODTs by HPLC Method

Chromatographic conditions

- Column: Reversed phase C18 column.
- Mobile phase: Consisted of water (15 mM Ortho-phosphoric acid) and acetonitrile (50:50 v/v).
- Buffer: Ortho-phosphoric acid (min. 85%).
- Flow rate: 1 ml/minute.
- Injection volume: 10µ.
- Wavelength: 238nm.
- Temperature: 37°C.

Preparation of phosphate solution

Dissolve 4.1g of Ortho-phosphoric acid (min. 85%) in about 900ml of water in a 1000 ml volumetric flask, and adjust with phosphoric acid to a pH of 2.0. Dilute with water to volume, and mix.

Preparation of diluent solution

Prepare a mixture of water and menthol (4:1).

Preparation of standard solution

Dissolve an accurately weighed quantity of USP 20mg of Furosemide and 5mg of Amlodipine. transferred into a 100 mL calibrated flask, diluted with methanol, stirred for about 10 min and then completed to volume with the same solution into a 100 mL then take 1ml from this solution and diluted with methanol into a 10mL.

Preparation of sample solution

5 tablets containing individually 20mg of Furosemide and 5mg of Amlodipine were finely powdered separately. An accurate weight of the powder equivalent to one tablet content was weighed, transferred into a 100 mL calibrated flask, diluted with methanol, stirred for about 10 min and then completed to volume with the same solution into a 100 mL then take 1ml from this solution and diluted with methanol into a 10 ml after filtration, the methods were established by triplicate injections of solutions containing Furosemide and Amlodipine.

Sample injection procedure

Separately inject equal volumes (about 10 µl) of the Standard preparation and the assay preparation into the chromatograph, record the chromatograms, and measure the area responses for the major peaks.

Calculate the quantity, in mg, of Furosemide and Amlodipine in each tablet taken by formula: $(L/D) C$ (ru/rs) L: is labeled quantity, in mg of Furosemide and Amlodipine in each tablet. D: is concentration, in mg/ml of Furosemide and Amlodipine of sample preparation. C: is the concentration calculate on the anhydrous basis of USP

Furosemide and Amlodipine in standard preparation. ru and rs: are the peak area responses obtained from standards and sample preparation.

In-vitro Dissolution Studies of Furosemide and Amlodipine ODTs

The *in-vitro* drug release was determined by estimating the dissolution profile. USP I Basket apparatus was used and Basket was allowed to rotate at 50 rpm. Phosphate buffer (pH 6.8) 900 ml was used as a dissolution medium at $37 \pm 0.5^\circ\text{C}$ temperature. Determination of amount of drug dissolved from tablets was carried by UV Spectrophotometer. In this test, six tablets from each batch were used for the studies. At specified time intervals (5, 10, 30), 5 ml of samples were collected and immediately replaced with an equal volume of fresh medium. Samples were analyzed by using UV Spectrophotometer at 276nm and 238nm respectively using phosphate buffer as blank.

RESULTS AND DISCUSSION**Evaluation of Furosemide and Amlodipine Orodispersible Tablets****Table 3: Results of Post Compression Weight Variation (mg) ODTs.**

NO	Weight Variation (mg)					
	F1	F2	F3	F4	F5	F6
1	188	147	165	150	155	147
2	160	159	155	148	152	158
3	185	146	150	147	149	147
4	148	141	149	167	147	147
5	155	144	147	145	148	149
6	154	154	148	146	151	150
7	127	143	152	162	146	155
8	143	158	154	148	158	148
9	160	147	147	151	150	152
10	131	147	148	149	148	154
Total	1551	1486	1514	1513	1513	1500
Average weight(X)	155.1	148.6	151.4	151.3	151.3	150
SD=X*7.5%	11.6	11.1	11.3	11.34	11.34	11.25
Lower Range	143.5	137.5	140.1	140	140	138.75
Higher Range	166.7	159.7	162.7	162.6	162.6	161.25

All formulations of and Furosemide and Amlodipine ODTs passed the weight variation test since the values are within the acceptable variation limit of the tablet as shown in Table 3.

Table 4: Evaluation of Post Compression Parameters of Furosemide and Amlodipine Formulations ODTs.


Formulation Code	Average Weight(mg)±S.D	Thickness (mm)	Diameter (mm) ± S.D	Friability %	Hardness Kg/cm ²	In-Vitro Disintegration (Sec)Time
F1	155±0.6	5.3±0.04	8.19±0.41	0.66±0.01	10±0.15	3
F2	148±0.7	5.4±0.04	8.17±0.41	0.65±0.02	9.2±0.12	2
F3	151±0.5	5.3±0.02	8.41±0.42	1.10±0.03	10±0.15	4
F4	151±0.6	5.4±0.04	8.45±0.42	0.38±0.03	9.8±0.14	9
F5	151±0.7	5.3±0.04	8.41±0.42	0.07±0.01	11±0.25	5
F6	150±0.6	5.3±0.02	8.42±0.42	0.47±0.03	12±0.30	7

As shown in Table 4, the hardness of the tablets for all formulations was measured and the values were found in the range between 9.2 to 12 kg/cm². The prepared tablets possessed good mechanical strength with sufficient hardness. The thickness of the tablets was measured and were found in the range between 5.3± 0.149 mm to 5.4±0.1755 mm. All the formulations possessed uniform thickness and in the accepted range. The diameter of the tablets was measured and were found in the range between 8.17± 0.41 mm to 8.45±0.42 mm. All the formulations possessed uniform diameter and in the accepted range. Similarly, percentage friability values of the prepared Furosemide and Amlodipine ODTs showed less than 1% weight loss that is highly within the acceptable limit except F3 it showed more than 1% weight loss (present capping). Disintegration time was

determined and the best disintegration time taken for the formulation F2 was found to be 2 seconds. The order of disintegration time of formulations with respect to super disintegrant was found to be crospovidone more effect than sodium starch glycolate. As the concentration of superdisintegrants in the formulations increases, the time taken for disintegration decrease.

Assay of Furosemide and Amlodipine by HPLC Method

The assay was carried out by HPLC method as per the procedure given in methods. The HPLC chromatogram of Furosemide and Amlodipine standard and sample formulations were shown in Figures (1-6) and Tables (5-10).

**Fig. 1: HPLC Chromatogram of STD-01.****Table 5: Assay of Furosemide and Amlodipine of STD-01.**

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.235	1942237	37344	620	6.83162	2.42575
Amlodipine	2.658	24013685	2084951	1176	0.00000	1.02847
Total	10.893	25955922	2122295	1796	6.83162	1.02847




Fig. 2: HPLC Chromatogram of STD-02.

Table 6: Assay of Furosemide and Amlodipine of STD-02.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.143	1907267	37356	645	6.92314	2.36987
Amlodipine	2.622	23947768	2065554	1128	0.00000	1.02283
Total		25855035	2102910			




Fig. 3: HPLC Chromatogram of STD-03.

Table 7: Assay of Furosemide and Amlodipine of STD-03.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.138	1912228	37314	632	6.85712	2.40736
Amlodipine	2.627	23783809	2061908	1133	0.00000	1.02434
Total	10.765	25696037	2099222	1765	6.85712	4.4317




Fig. 4: HPLC Chromatogram of STD-04.

Table 8: Assay of Furosemide and Amlodipine of STD-04.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.127	1920093	37569	641	6.90632	2.42528
Amlodipine	2.617	23879924	2066972	1129	0.00000	1.02005
Total	10.744	25800017	2104541	1770	6.90632	3.44533




Fig. 5: HPLC Chromatogram of STD-05.

Table 9: Assay of Furosemide and Amlodipine of STD-05.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.118	1898961	37275	643	6.89175	2.36597
Amlodipine	2.608	23906202	2044896	1076	0.00000	1.02209
Total	10.726	25805163	2082171	1719	6.89175	3.38806




Figure 6: HPLC Chromatogram of STD-06.

Table 10: Assay of Furosemide and Amlodipine of STD-06.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.105	1906727	37260	630	6.83124	2.39035
Amlodipine	2.598	23912757	2038230	1052	0.00000	1.01777
Total	10.703	25819484	2075490	1682	6.83124	3.40812




Fig. 7: HPLC Chromatogram of Formulation F1.

Table 11: Assay of Furosemide and Amlodipine of Formulation F1.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.105	1940799	38088	604	6.72989	2.20979
Amlodipine	2.600	23394872	2004479	1080	0.00000	1.01657
Total	10.705	25335671	2042567	1684	6.72989	3.22636




Fig. 8: HPLC Chromatogram of Formulation F2.

Table 12: Assay of Furosemide and Amlodipine of Formulation F2.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.113	1913176	37053	614	6.76682	2.25851
Amlodipine	2.603	23491048	1999975	1067	0.00000	1.01415
Total	10.716	25404224	2037028	1681	6.76682	3.27266




Fig. 9: HPLC Chromatogram of Formulation F3.

Table 13: Assay of Furosemide and Amlodipine of Formulation F3.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.153	1728088	33875	642	6.90328	2.18856
Amlodipine	2.613	22018424	1885029	1080	0.00000	1.01321
Total	10.766	23746512	1918904	1722	6.90328	3.20177




Fig. 10: HPLC Chromatogram of Formulation F4.

Table 14: Assay of Furosemide and Amlodipine of Formulation F4.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.053	1896686	37205	622	6.78229	2.26212
Amlodipine	2.588	23141630	1979757	1048	0.00000	1.00669
Total	10.641	25038316	2016962	1670	6.78229	3.26881




Fig. 11: HPLC Chromatogram of Formulation F5.

Table 15: Assay of Furosemide and Amlodipine of Formulation F5.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.045	1926187	37903	624	6.78648	2.28192
Amlodipine	2.585	23385263	1999382	1040	0.00000	1.01716
Total	10.63	25311450	2037285	1664	6.78648	3.29908




Fig. 12: HPLC Chromatogram of Formulation F6.

Table 15: Assay of Furosemide and Amlodipine of Formulation F6.

Name of drug	Retention Time	Area	Height	Theoretical Plates (USP)	Resolution (USP)	Asymmetry
Furosemide	8.053	1863222	36684	631	6.82996	2.26136
Amlodipine	2.583	22724328	1952295	1050	0.00000	1.01329
Total	11.113	24587550	1988979	1681	6.82996	3.27465

Table 16: Assay of Furosemide and Amlodipine ODTs.

No	Furosemide Recovery%*± SD	RSD%	Amlodipine Recovery%* ± SD	RSD%
F1	100.80 ± 0.983	0.976	97.56 ± 0.510	0.520
F2	99.84 ± 0.151	0.151	97.83 ± 0.740	0.756
F3	90.84 ± 0.503	0.554	91.64 ± 0.390	0.429
F4	99.57 ± 0.438	0.440	96.80 ± 0.001	0.001
F5	100.97 ± 0.313	0.310	97.81 ± 0.004	0.004
F6	97.52 ± 0.176	0.180	95.05 ± 0.001	0.001

Average of Three Determinations*.

The HPLC chromatogram of Furosemide and Amlodipine ODTs formulations were shown in Figures (7-12) and Tables (6-16). Assay of Furosemide and Amlodipine ODTs formulations following the procedure of the reported RP-HPLC method for the binary mixture of the standard substances and the formulated 6 formulations, the following data were obtained. Sample and standard concentrations of Furosemide and Amlodipine (20 and 5 µg/mL respectively), the results in the Table 16, showed that the assay of Furosemide ODTs (F1-F6) were found in the range between 90.84%

to 100.80 %. The assay of Amlodipine ODTs (F1-F6) were found in the range between 91.64% to 97.81%. The acceptable limit of Furosemide and Amlodipine content, and thus complied with the USP standard of drug content (90 to 110%). The results revealed that the assay of Amlodipine and Furosemide was within the acceptable limits.

In-vitro dissolution studies

The in -vitro drug release of Amlodipine and Furosemide formulations ODTs were given in Tables 17 and 18.

Table 17: Percentage of Drug Release of Furosemide Formulations ODTs.

Formulation Code	Percentage Drug Release (%)		
	Time (min)		
	5	10	30
F1	42.90%	72.80%	69.94%
F2	43.26%	62.57%	75.08%
F3	55.15%	73.05%	88.83%
F4	76.51%	58.32%	73.01%
F5	75.27%	75.79%	75.27%
F6	60.58%	57.91%	57.12%

Table 18: Percentage of Drug Release of Amlodipine Formulations ODTs.

Formulation Code	Percentage Drug Release (%)		
	Time (min)		
	5	10	30
F1	82.82%	91.97%	92.35%
F2	90.72%	94.91%	97.56%
F3	86.57%	87.57%	88.46%
F4	82.74%	87.77%	94.70%
F5	83.29%	86.30%	83.29%
F6	71.28%	73.48%	84.27%

The *in-vitro* dissolution profile of Furosemide and Amlodipine is one of the most important experiments to prove if the ODTs are convenient to be used for rapid action. This study was applied to all formulations by using in phosphate buffer (pH 6.8) at time interval (5, 10, 30 minutes) digital dissolution tester at (37± 0.5°C).

Amlodipine and furosemide release were studied in Phosphate Buffer pH (6.8) for up to 30 minutes. The formulation F1 F2 F3 (crospovidone), F4 F5 F6 (sodium starch glycolate) were prepared along with microcrystalline cellulose, aspartame, magnesium stearate and sodium lauryl sulphate. The drug release of formulation F1, F2 and F3 was found to be 69.94 % ,75.08 % and 88.83% and the drug release of formulation F4 F5 F6 was found to be 73.01 % ,75.27 % and 57.12% at 30 minutes for Furosemide. The drug release of formulation F1, F2 and F3 was found to be 92.35%, 97.56% and 88.46% and the drug release of formulation F4 F5 F6 was found to be 94.70%, 83.29% and 84.27% at 30 minutes for Amlodipine.

From the above results and discussion, it was concluded that formulation of Orodispersible tablets of Furosemide and Amlodipine containing crospovidone such as F1, F2 and F3 can be taken as an optimized formulation of Furosemide Orodispersible tablets for drug release 42.90%, 43.26% and 55.15% release within 5 minutes while F1, F2 and F3 can be taken as an optimized formulation of Amlodipine Orodispersible tablets for drug release 82.82%, 90.72% and 86.57% release within 5 minutes. The formulations containing sodium starch glycolate such as F4, F5 and F6 can be taken as an optimized formulation of Furosemide Orodispersible tablets for drug release 76.51%, 75.27% and 60.58% release within 5 minutes while F4, F5 and F6 can be taken as an optimized formulation of Amlodipine Orodispersible tablets for drug release 82.74%, 83.29% and 71.28% release within 5 minutes. The present study shows that the dissolution rate of Furosemide and Amlodipine can be enhanced through the great extent by addition of superdisintegrant methods. The rapid drug dissolution might be due to easy breakdown of the particles due to porous structure formation after superdisintegration addition method and rapid absorption of drugs into the dissolution medium.

CONCLUSION

Furosemide and Amlodipine were selected as a model for preparation of Orodispersible Tablets ODTs by direct compression technique. Amlodipine is a long-acting calcium channel blocker (dihydropyridine) used as an anti-hypertensive and in the treatment of angina. Furosemide is a loop diuretic commonly used in adults, infants and children for the treatment of edematous states associated with congestive heart failure, cirrhosis of the liver and renal disease. Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Orodispersible tablets ODTs of Furosemide and Amlodipine were prepared by direct compression method using, and crospovidone and sodium starch glycolate as superdisintegrants. The tablets disintegrated rapidly in oral cavity and had acceptable hardness and friability. The *in-vitro* drug release from the tablets shows significantly improved drug dissolution. Hence it could be concluded that the superdisintegrant based Orodispersible tablets of Furosemide and Amlodipine would be quite effective in providing quick onset of action without need for water for swallowing or administration. In order to improve onset of action and increase bioavailability Furosemide and Amlodipine were developed as Orodispersible tablets. The results of *in-vitro* disintegration time of F4 and F2 was found to be 9 and 2 seconds and the drug release 90.72% and 76.51% at 5 minutes respectively indicated that the tablets dispersed rapidly in the mouth. It was concluded that F4 and F2 are the best formulations of Furosemide and Amlodipine Orodispersible Tablets ODTs drug delivery systems in order to increase onset of action and bioavailability of drug.

ACKNOWLEDGEMENT

The authors are thankful to Biopharm Pharmaceutical Industry Company-Yemen, and Shaphaco Pharmaceutical Industry Company-Yemen, for their support and facilities.

REFERENCES

1. Zhang F, Mao J, Tian G, Jiang H, Jin Q. Preparation and characterization of furosemide solid dispersion with enhanced solubility and bioavailability. AAPS PharmSciTech, 2022; 23(1): 65.

2. Kumar S, Kumar M. Preformulation study of furosemide. *Der Pharmacia Lettre*, 2016; 8(13): 214-222.
3. Martindale "The Extrapharmacopoeia", Sweetman SC, (Eds), London, U.K., Pharmaceutical Press, 2007; 35.
4. Physician Desk Reference (PDR), Sanborn KD, (Eds), New Jersey USA, Medical Economics Co., Montvale, 2007; 61.
5. Gaurav, et al. Formulation and Evaluation of Disintegrating Tablet of Famotidine. *Pharmaceutical Science Monitor* Jan-Mar, 2015; 6(1): 75- 93.
6. Bamanian BN. Formulation and Evaluation of Fast Dissolving Famotidine Solid Dispersion Tablet. *American Journal of Pharmaceutical and Technology Research*, 2013; 3(5).
7. Furtado S. Development and Characterization of Orodispersible Tablets of Famotidine Containing a Subliming Agent. *Tropical Journal of Pharmaceutical Research*, 2008; 7(4): 1185-1189.
8. Sukhavasi S. Formulation and Evaluation of Fast Dissolving Tablets of Amlodipine Besylate by Using Fenugreek Seed Mucilage and Ocimum Basilicum Gum. *International Current Pharmaceutical Journal*, 2012; 1(9): 243-249.
9. Vimalson DC, Anbazhagan S, Gokul L, Idhayadharani S, Ranjith S, Sabarinathan J, Surya R. Enhancement of solubility and dissolution characteristics of furosemide by solid dispersion. *World Journal of Pharmaceutical Research*, 2019; 11(8): 696-719.
10. Goodman and Gilman's, "The Pharmacological Basis of Therapeutics", Brunton LL., (Eds), New York, USA, McGraw-Hill Medical Publications Division, 2006; 11.
11. Mascoli V, Kuruganti U, Bapuji A, Wang R, Damle B. Pharmacokinetics of a Novel Orodispersible Tablet of Amlodipine in Healthy Subjects. *J Bioequiv Availab*, 2013; 5: 76-9.
12. Liu Y, Jia J, Liu G, Li S, Lu C, Liu Y, Yu C. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. *Clin Ther*, 2009; 31(4): 777-83.
13. Berko S, Regdon G, Jr., Ducza E, Falkay G, Eros I. In vitro and in vivo study in rats of rectal suppositories containing furosemide. *Eur J Pharm Biopharm*, 2002; 53(3): 311-5.
14. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. *Br J Clin Pharmacol*, 2007; 64(6): 804-9.
15. Regdon G, Fazekas T, Regdon G, Selmeczi B. [Formulation and in vitro examination of furosemide-containing suppositories and preliminary experiences of their clinical use]. *Acta Pharm Hung*, 1997; 67(1): 19-23.
16. Uchida T, Yoshida M, Hazekawa M, Haraguchi T, Furuno H, Teraoka M, Ikezaki H. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor. *J Pharm Pharmacol*, 2013; 65(9): 1312-20.
17. Jang DJ, Bae SK, Oh E. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients. *Biomed Pharmacother*, 2014; 68(8): 1117-24.
18. Unia B, Varun j. Formulation and evaluation of orodispersible tablet of amlodipine besilate. *International Journal Of Pharmacy&Technology*, 2011; 3(4): 3745-66.
19. Mohanachandran PS, Krishna Mohan PR, Fels S, Bini KB, Beenu B, SHalina KK. Formulation and evaluation of mouth dispersible tablets of amlodipine besylate. *Int J Appl Pharma*, 2010; 2(3): 1-6.
20. Roy A. Orodispersible tablets: a review. *Asian J Pharm Clin Res*, 2016; 9: 19-26.
21. Srikrishna S, Cardozo L. The vagina as a route for drug delivery: a review. *Int Urogynecol J*, 2013; 24(4): 537-43.
22. Brunton L, Chabner B, Knollmann B. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill, 2011.
23. Santosh R, Kumar T, Yagnesh NS. Orodispersible Systems – an Alternative Approach for Enhanced Therapeutic Action. *Indo American Journal of Pharmaceutical Research*, 2018; 8(12).
24. Rahane RD, Rachh PR. A Review on Orodispersible Tablet. *Journal of Drug Delivery and Therapeutics*, 2018; 8(5): 50-55.
25. Nagar P, et al. Orally Disintegrating Tablets: Formulation, Preparation Techniques and Evaluation. *Journal of Applied Pharmaceutical Science*, 2011; 01(04): 35-45.
26. Nehal SM, Garima G, Pramod KS. Fast Dissolving Tablets: Preparation, Characterization and Evaluation: an Overview. *Int J Pharm Sci Rev Res*, 2015; 31(2): 243-250.
27. Deshmukh H, Chandrashekhara S, Nagesh C, Murade A, Usgaunkar S. Superdisintegrants: a Recent Investigation and Current Approach. *Asian J Pharm Tech*, 2012; 2: 19-25.
28. BNF. BMJ Group and Royal Pharmaceutical Society. September 2022-March, 2023; S140-S141.
29. Preston CL. Stockley's Drug Interaction Pocket Companion. Pharmaceutical Press., 2015; 2: S119-S576.
30. Borse LB, Bendale AR, Borse SL, Naphade VD, Jadhav AG. Formulation and Evaluation of Mouth Dissolving Tablet Rivaroxaban and its Validation. *Biosci Biotechnol Res Asia*, 2022; 19(4): 943-954.
31. Stuart BH. Infrared Spectroscopy: Fundamentals and Applications. Wiley, 2004; 1: S168.
32. Raymond C. R, Sheskey PJ, Owen CS. Handbook of Pharmaceutical Excipients Fifth Edition Edited.
33. Shivangi S, Navneet V. Taste Masked Orodispersible Tablets. A highly patient Compliant

- Dosage Form. *Asian J Pharm Clin Res*, 2016; 9: 385-91.
34. Anupam R. Orodispersible Tablets: A Review. *Asian J Pharm Clin Res*, 2016; 9: 19-26.
35. Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier J, Piccerelle P. Determination of The Invitro Disintegration Profile of Rapidly Disintegrating Tablets and Correlation with Oral Disintegration. *Int J Pharm*, 2005; 292: 29-41.
36. Anusha P, Nirajana A, Mohammed S, Jilani S, Murali C, Harish G. Development and Evaluation of Drotaverine Taste Masked Tablets with Improved Dissolution Efficiency Using Solid Dispersion Technique. *IJRPB*, 2013; 1: 275-80.
37. Srikanth M, Uhumwangho M, Sunil S, Sreenivasa N, Ravi C, Ramana Murthy K. Design and Revaluation of Taste Masked Drotaverine HCl Orodispersible Tablets Using Polymethacrylate Polymers. *Der Pharmacia Lett*, 2010; 2: 223-31.
38. Narasimhulu et al. Formulation and Evaluation of Orodispersible Drotaverine Sublingual Tablets. *Indo American Journal of Pharm Sciences*, 2014; 1(06).
39. Rele RV, Ruparel DG. UV Spent to Photo Metric Estimation of Drotaverine Hydrochloride by Derivative Method in Pharmaceutical Dosage Form. *International Journal of ChemTech Research*, 2018; (10): 353-360.
40. Shirwaikar AC. Galan Fast Disintegrating Tablets of Famotidine by Dry Granulation Method. *Ind J Pharm Sci*, 2004; 66: 422-426.
41. Venkateswarlu B, et al. Formulation and Evaluation of Famotidine Fast Dissolving Tablets by Direct Compression Method. *Indian Journal of Research in Pharmacy and Biotechnology*, 2013; 9-10(609): 609-613.
42. Sunada H, Bi YX. Preparation, Evaluation and Optimization of Rapidly Disintegrating Tablets. *Powder Technol*, 2002; 188-198.
43. Pires SA, Mussel WN, Yoshida MI. Solid-State Characterization and Pharmaceutical Compatibility between Citalopram and Excipients Using Thermal and Non-Thermal Techniques. *J Therm Anal Cal*, 2017; 127: 535- 542.
44. Joshi BV, Patil VB, Pokharkar VB. Compatibility Studies between Carbamazepine and Tablet Excipients Using Thermal and Non-Thermal Methods. *Drug Devel Ind Pharm*, 2002; 28: 687-694.
45. Reddy RA, Ramesh B, Kishan V. Drug-Excipient Interaction During Formulation Development In - Vitro and In -Vivo Evaluation of Gastroretentive Drug Delivery System for Nizatidine. *Int J Pharm Sci Nanotech*, 2013; 6: 2281-2293.
46. Prathyusha CH, Murthy TEGK. Compatibility Studies of Donepezil with Different Excipients by Using HPLC and FTIR. *J Adv Pharm Tech Res*, 2013; 3: 273-278.
47. Jangde R, Singh D. Compatibility Studies of Quercetin with Pharmaceutical Excipients used in The Development of Novel Formulation. *Research J Pharm and Tech*, 2014; 7: 1101-1105.
48. Shirwaikar AC. Galan Fast Disintegrating Tablets of Famotidine by Dry Granulation Method. *Ind J Pharm Sci*, 2004; 66: 422-426.
49. Venkateswarlu B, et al. Formulation and Evaluation of Famotidine Fast Dissolving Tablets by Direct Compression Method. *Indian Journal of Research in Pharmacy and Biotechnology*, 2013; 9-10(609): 609-613.
50. Khan MI, Madni A, Ahmad S, Khan A, Rehman M, Mahmood MA. ATRFTIR Based Pre and Post Formulation Compatibility Studies for The Design of Niosomal Drug Delivery System Containing Nonionic Amphiphiles and Chondroprotective Drug. *J Chem Soc Pak*, 2015; 37: 527-534.
51. Allen L, Ansel H. *Pharmaceutical Dosage Forms and Drug Delivery Systems* by Ansel (10th Edition). Lippincott Williams & Wilkins, Philadelphia, 2014.
52. Beringer P, Gupta PK, Felton L. *Stability of Pharmaceutical Products*. Remington: The Science and Practice of Pharmacy, 2005; 01: 1029-30.
53. Lena Ohannesian, Antony J. Streeter. *Handbook of Pharmaceutical Analysis*, Marcel Dekker, Inc, 2002.
54. Banker G, Rhodes CT. *Modern Pharmaceutics*, Marcel Dekker, Inc, 2000.
55. ICH Topic Q8 (R2). *Pharmaceutical development*, 2009; 8.
56. Michael E Aulton, *Pharmaceutics- The Sciences of Dosage Form Design*, 4th International Edition, Churchill Livingstone, USA, 2013; 367-389.
57. Leon Lachman, Lieberman's. *The Theory and Practice of Industrial Pharmacy*. Indian 4th Edition, CBS Publisher, Reprint, 2020; 217-251.
58. WHO. Annex (3). *Pharmaceutical Development of Multisource (Generic) Finished Pharmaceutical Products*.
59. Rewar S, Singh CJ, Bansal BK, Pareek R, Sharma AK. Oral Dispersible Tablet: an Overview, Development, Technologies and Evaluation. *Int J Res Dev Pharma Life Sci*, 2014; 3(4, 6): 1223-35.
60. <https://go.drugbank.com/drugs/DB00695>.
61. <https://pubchem.ncbi.nlm.nih.gov/compound/Furosemide>
62. <https://go.drugbank.com/salts/DBSALT001054>.
63. <https://pubchem.ncbi.nlm.nih.gov/compound/Amlodipine-Besylate>
64. Sunil Kumar BG, Felix JV, Vishwanath BA. Formulation and Evaluation of Dispersible Tablet of Cefixime Trihydrate. *Int J Pharma Drug Analysis*, 2014; 2(1): 858-68.
65. Walke PS, Pawar AY, Sonawane DD, Bhamber RS. *Liquisolid. A Novel Technique to Enhance Solubility and Dissolution Rate of BSC Class II Pharmaceutical*. *J Pharm Res*, 2011; 4(11): 4011-4.
66. Brough C, Williams RO. Amorphous Solid Dispersions and Nanocrystal Technologies for Poorly Water-Soluble Drug Delivery. *Int J Pharm*, 2013; 453: 157-66.

67. Samal HB, Debata. Solubility and Dissolution Improvement of Aceclofenac Using β -Cyclodextrin. *Int J Drug Dev Res*, 2012; 4: 326-33.
68. Hrishav DP, Nath B. Formulation and Evaluation of Oral Fast Disintegrating Tablet of Ibuprofen Using Two Super Disintegrants. *Int J Curr Pharm Res*, 2017; 9: 92-5.
69. Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The Applications of Vitamin E TPGS in Drug Delivery. *Eur J Pharm Sci*, 2013; 49(2): 175-86.
70. Bary AA, El-Gazayerly ON, Alburyhi MM. A Pharmaceutical Study on Lamotrigine. Ph.D. Thesis, Faculty of Pharmacy, Cairo University, 2009.
71. Alburyhi MM, Salim YA, Saif AA, Noman MA. Furosemide-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(22): 1178-1219.
72. Alburyhi MM, Salim YA, Saif AA, Noman MA. Amlodipine-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(11): 95-136.
73. Alburyhi MM, Saif AA, Noman MA. Lornoxicam-Excipient Compatibility Studies for Microsponge-Based Drug Delivery Systems Development. *World Journal of Pharmaceutical and Medical Research*, 2025; 11(4): 70-81.
74. Hamidaddin MA, Alburyhi MM, Noman MA, Saif AA. Formulation and Evaluation of Rosuvastatin Fast Dissolving Tablets. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2023; 12(9): 2293-2303.
75. Alburyhi MM, Hamidaddin MA, Noman MA, Saif AA, Yahya TA, Al-Ghorafi MA. Rivaroxaban-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *European Journal of Pharmaceutical and Medical Research*, 2024; 11(9): 370-404.
76. Bary AA, El-Gazayerly ON, Alburyhi MM. Formulation of Immediate Release Lamotrigine Tablets and Bioequivalence Study. *Journal of Chemical Pharm Research*, 2013; 5(10): 266-271.
77. Saif AA, Alburyhi MM, Noman MA, Yahya TA, Al-Ghorafi MA. Famotidine-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(18): 1346-1408.
78. Alburyhi MM, Noman MA, Saif AA, Al-Ghorafi MA, Al Khawlani MA, Yahya TAA. Formulation and Evaluation of Anti-acne Spironolactone Emulgel Novel Trend in Topical Drug Delivery System. *World Journal of Pharmaceutical Research*, 2023; 12(22): 96-119.
79. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Pandanus Odoratissimus Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Breast Cancer. *World Journal of Pharmaceutical Research*, 2024; 13(8): 1092-1112.
80. Alburyhi MM, Noman MA, Saif AA, Salim YA, Hamidaddin MA, Yahya TA, Al-Ghorafi MA, Abdullah JH. Lisinopril-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(16): 59-111.
81. Al-Ghorafi MA, Alburyhi MM, Saif AA, Noman MA, Yahya TA. Drotaverine-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(18): 1285-1340.
82. Alburyhi MM, Noman MA, Saif AA, Hamidaddin MA, Yahya TA, Al-Ghorafi MA. Rosuvastatin-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(13): 1549-1582.
83. Alburyhi MM, Saif AA, Noman MA. Ticagrelor-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(10): 1081-1132.
84. Alburyhi MM, Noman MA, Saif AA, Al-Ghorafi MA, Yahya TA, Yassin SH, Al Khawlani MA. Diclofenac-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(14): 1297-1333.
85. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Aloe Vera Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Controlling Diabetes. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(4): 1408-1423.
86. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Curcuma Longa Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Cancer. *European Journal of Biomedical and Pharmaceutical Sciences*, 2024; 11(6): 37-43.
87. Alburyhi MM, Saif AA, Noman MA, Salim YA, Hamidaddin MA. Formulation and Evaluation of Lisinopril Orally Disintegrating Tablets. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2023; 12(9): 357-369.
88. Alburyhi MM, Saif AA, Noman MA. Stability Study of Six Brands of Amoxicillin Trihydrate and Clavulanic Acid Oral Suspension Present in Yemen Markets. *Journal of Chemical Pharm Research*, 2013; 5(5): 293-296.
89. Alburyhi MM, El-Shaibany A. Formulation and Evaluation of Antitumor Activity of Artemisia Arborescence Extract Capsules as Dietary Supplement Herbal Product Against Breast Cancer. *World Journal of Pharmaceutical Research*, 2024; 13(3): 95-114.
90. Alburyhi MM, Hamidaddin MA, Saif AA, Noman MA. Formulation and Evaluation of Rivaroxaban Orodispersible Tablets. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(2): 2066-2092.

91. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Aloe Vera Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Cancer. *World Journal of Pharmaceutical Research*, 2024; 13(8): 1052-1072.
92. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Aloe Rubroviolaceae Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Hepatoprotective. *European Journal of Biomedical and Pharmaceutical Sciences*, 2024; 11(4): 53-61.
93. Alburyhi MM, Saif AA, Noman MA, Yahya TA. Formulation, Development and Evaluation of Famotidine Orodispersible Tablets. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(10): 56-62.
94. Alburyhi MM, Saif AA, Noman MA, Saif RM. Recent Innovations of Delivery Systems for Antimicrobial Susceptibility Study of Ciprofloxacin Biodegradable Formulations for Post-Operative Infection Prophylaxis. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(9): 32-36.
95. Aboghanem A, Alburyhi MM, Noman MA. Effect of Different Excipients on Formulation of Immediate Release Artemether/Lumefantrine Tablets. *Journal of Chemical Pharm Research*, 2013; 5(11): 617-625.
96. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Dictyota Dichotoma Extract Medicinal Seaweed Capsules Delivery System as an Advanced Phytotherapy Approach for Cancer. *European Journal of Biomedical and Pharmaceutical Sciences*, 2024; 11(4): 63-70.
97. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Celery Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Gout. *World Journal of Pharmaceutical Research*, 2024; 13(11): 2383-2404.
98. Raweh SM, Noman MA, Alburyhi MM, Saif AA. Formulation and Evaluation of Anti-acne Gel of Azadirachta Indica Extract Herbal Product. *European Journal of Pharmaceutical and Medical Research*, 2024; 11(2): 427-433.
99. Alburyhi MM, Saif AA, Noman MA. Formulation and Evaluation of Ticagrelor Orodispersible Tablets. *World Journal of Pharmaceutical Research*, 2024; 13(5): 26-55.
100. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Tribulus Terrestris Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Kidney Stones. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(5): 1425-1443.
101. Alburyhi MM, Saif AA, Noman MA, Yahya TA, Al-Ghorafi MA. Formulation and Evaluation of Drotaverine Orally Disintegrating Tablets. *World Journal of Pharmaceutical Research*, 2023; 12(18): 66-79.
102. Lipinski CA, Lombardo. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. *Adv Drug Deliv Rev*, 2011; 46: 3-26.
103. Cortese F, Gesualdo M, Cortese A, et al. Rosuvastatin: Beyond the Cholesterol-Lowering Effect. *Pharm Res-Dordr*, 2016; 107: 1-18.
104. McTaggart F. Comparative Pharmacology of Rosuvastatin. *Atherosclerosis Supp*, 2003; 4: 9-14.
105. Iqbal MK, Singh PK, Shuaib M, et al. Recent Advances in Direct Compression Technique for Pharmaceutical Tablet Formulation. *Int J Pharm Res Develop*, 2014; 6: 49-57.
106. Chavan H, Chhabra G, Gujarathi N, et al. Comparative Study of in-Process and Finished Products Quality Control Test for Tablet and Capsules According to Pharmacopoeias. *Asian J Pharm Res Develop*, 2018; 6: 60-68.
107. Bozal-Palabiyik B, Uslu B, Ozkan Y, et al. In-Vitro Drug Dissolution Studies in Medicinal Compounds. *Curr Med Chem*, 2018; 25: 4020-4036.
108. Jain P, Goel A, Sharma S, Parmar M. Solubility Enhancement Techniques with Special Emphasis on Hydrotrophy. *International Journal of Pharmaceutical Research*, 2009; 1(1): 34-45.
109. Patil S K, Wagh K S, Parik V B, Akarte A M, Baviskar D T. Strategies for Solubility Enhancement of Poorly Soluble Drugs. *Int J Pharm Sci Rev Res*, 2011; 8(2): 74-80.
110. Tyagi S, Patel C, Dadrwal P, Mangukia D, Sojitra I, Nimbiwal Bk, Singh V, Subrahmanyamkv. A Novel Concept for Solubilization and Bioavailability of Poorly Soluble Drugs: Hydrotrophy. *Int J Pharmes and Bio Sci*, 2013; 2(1): 372-381.
111. Aulton's Pharmaceuticals: Pharmaceuticals-the Science of Dosage Forms Design. Churchill Livingstone Elsevier, 2007; 3: 322-538.
112. Jagtap S, Magdum C, Jadge D, Rajesh Jagtap R. Solubility Enhancement Technique: A Review Published by *Journal of Pharmaceutical Sciences & Research*, 2018; 10(9): 2205-2211.
113. Chavda HV, Patel CN, Anand IS. A Review Article on Biopharmaceutics Classification System: Published by *Systematic Reviews in Pharmacy*, January-June, 2010; 1(1).
114. Shukla AK, et al. Review Article on Biopharmaceutical Classification System: Tool Based Prediction for Drug Dosage Formulation, *Advance Pharmaceutical Journal*, 2017; 2(6): 204-209.
115. Verma S, Rawat A, Kaul M, Saini S. Solid Dispersion: A Strategy for Solubility Enhancement. *Int J Pharm Technol*, 2011; 3: 1062-99.
116. Vidya N. Remington the Science & Practice of Pharmacy 21st Edition Volume 1st Lippincott Williams & Wilkins. *International Journal of Pharmaceutical Sciences and Research*, 2016; 7(12): 4882-4892.

117. Lindenberg M, Kopp S, Dressman J. Classification of orally administered drugs on the WHO model list of essential medicines according to biopharmaceutical classification system. *European Journal of Pharmaceutics & Biopharmaceutics*, 2004; 58(2): 265-278.
118. Jatwani S, Rana AC, Singh G, Aggarwal G. An Overview on Solubility Enhancement Techniques for Poorly Soluble Drugs and Solid Dispersion as an Eminent Strategic Approach. *International Journal of Pharmaceutical Sciences and Research*, 2012; 3(4): 942-956.
119. Thorat YS, Gonjari ID, Hosmani AH. Solubility Enhancement Techniques: A Review on Conventional and Novel Approaches. *International Journal of Pharmaceutical Sciences and Research*, 2011; 2(10): 2501-2513.
120. Pokharkar V, Khanna A, Venkatpurwar V, Dhar S, Mandpe L. Ternary Complexation of Carvedilol, β -Cyclodextrin and Citric acid for Mouth-Dissolving Tablet Formulation. *Acta pharmaceutica*, 2009; 59(2): 121-132.
121. Patel VP, Soniwala MM. Pulsatile Drug Delivery System for Treatment of Various Inflammatory Disorders: A Review. *International Journal of Drug Development and Research*, 2012; 4(3).
122. Sandeep P, Venkateswara Reddy B, Navaneetha K. Formulation and Evaluation of Rosuvastatin Pulsatile Drug Delivery System by Using Press Coating Technique. *Int J Res Pharm Sci*, 2014; 5(1): 46-52.
123. Alburyhi MM, El-Shaibany A. Formulation and Evaluation of Effervescent Granules of Artemisia Arborecence Herbal Product for Foodborne Illness. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2023; 12(12): 1429-1444.
124. Alburyhi MM, Saif AA, Saif RM. Preformulation Study of Ceftriaxone and Ciprofloxacin for Lipid Based Drug Delivery Systems. *EJUA-BA*, 2022; 3(4): 339-350.
125. Alburyhi MM, Noman MA, Saif AA. Formulation and Evaluation of Natural Herbal Anti-acne as Gel Delivery Systems. *World Journal of Pharmaceutical Research*, 2024; 13(21): 1447-1467.
126. Noman MA, Alburyhi MM, Saif AA, Yahya TAA. Evaluation and Drug Stability Studies Some Atorvastatin Tablets Brands Available in Sana'a Market Yemen. *World Journal of Pharmaceutical and Medical Research*, 2024; 10(12): 231-236.
127. Alburyhi MM, Noman MA, Alemad AF. Preformulation Studies of Cefixime for Dispersible Tablets Delivery System Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(12): 75-99.
128. Al-Ghorafi MA, Alburyhi MM, Muthanna MS. Chemical Incompatibilities of IV Admixture Combinations in ICU, Orthopedic and Emergency Units of Various Hospitals and Medical Centers in Sana'a, Yemen. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(10): 416-425.
129. Noman MA, Alburyhi MM, Saif AA, Yahya TAA. Formulation and Evaluation of Polyherbal Extract for Skin Hyperpigmentation as Gel Advanced Delivery Systems. *World Journal of Pharmaceutical Research*, 2024; 13(22): 1260-1280.
130. Saif AA, Noman MA, Alburyhi MM, Yahya TAA. Evaluation and Drug Stability Studies Some Levocetirizine Tablets Brands Available in Sana'a Market Yemen. *World Journal of Pharmaceutical Research*, 2024; 13(24): 1009-1022.
131. Alburyhi MM, Noman MA, AA Saif. Formulation and Evaluation of Meloxicam Emulgel Delivery System for Topical Applications. *World Journal of Pharmaceutical Research*, 2025; 14(4): 1324-1337.
132. Alburyhi MM, El-Shaibany A, Al-Wajih AM, Alqadhi AA, Almlhani AN. Advancements in Nano-Formulation Systems for Enhancing the Delivery of Herbal Ingredients. *European Journal of Pharmaceutical and Medical Research*, 2025; 12(1): 212-231.
133. Al-Ghorafi MA, Alburyhi MM, Muthanna MS. Effect of Rosemary and Myrtus Extracts Combination on Androgenetic Alopecia: A Comparative Study with Minoxidil. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(10): 35-39.
134. Alburyhi MM, Noman MA, Saif AA, Alemad AF. Dispersible and Orodispersible Tablets Delivery Systems for Antibacterials Development. *World Journal of Pharmaceutical Research*, 2025; 14(1): 1229-1257.
135. Alburyhi MM, El-Shaibany A, Al-Wajih AM, Almlhani AN, Alqadhi AA. Innovative Approaches in Herbal Drug Delivery Systems Enhancing Efficacy and Reducing Side Effects. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2025; 14(1): 919-929.
136. Alburyhi MM, Saif AA, Noman MA, Saif RM. Recent Innovations of Delivery Systems for Antimicrobial Susceptibility Study of Ceftriaxone Biodegradable Formulations for Post-Operative Infection Prophylaxis. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 95-99.
137. Al-Ghorafi MA, Alburyhi MM, Saif AA, Noman MA. Meloxicam-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical and Medical Research*, 2025; 11(1): 87-106.
138. Alburyhi MM, Saif AA, Noman MA. Domperidone-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Biomedical and Pharmaceutical Sciences*, 2025; 12(3): 250-269.
139. Alburyhi MM, Saif AA, Noman MA. Spironolactone-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2025; 14(3): 871-910.

140. Saif AA, Alburyhi MM, Noman MA. Ketoprofen-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2025; 14(4): 92-123.
141. Alburyhi MM, Saif AA, Noman MA. Clopidogrel-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical Research*, 2025; 14(6): 1448-1486.
142. Alburyhi MM, Saif AA, Noman MA, Yassin SH. Formulation and Evaluation of Simvastatin Orodispersible Tablets. *World Journal of Pharmaceutical Research*, 2023; 12(16): 1033-1047.
143. Noman MA, Alburyhi MM, Alqubati MA. Preformulation and Characterization Studies of Clopidogrel Active Ingredient for Orodispersible Tablets Development. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(3): 996-1015.
144. Alburyhi MM, El-Shaibany A. Formulation and Evaluation of Anti-peptic Ulcer Capsules of Curcuma Longa Herbal Product. *World Journal of Pharmaceutical Research*, 2023; 12(22): 76-96.
145. Alburyhi MM, Saif AA, Noman MA, Al Ghoury AA. Formulation and Evaluation of Antimalarial Drugs Suppositories. *World Journal of Pharmaceutical Research*, 2023; 12(20): 89-108.
146. Alburyhi MM, Saif AA, Noman MA, Saeed SA, Al-Ghorafi MA. Formulation and Evaluation of Diclofenac Orodispersible Tablets. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(9): 01-06.
147. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Chamomile Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Gout. *World Journal of Pharmaceutical and Life Sciences*, 2025; 11(04): 215-228.
148. Alburyhi MM, Noman MA, Saif AA. Metronidazole-Excipient Compatibility Studies for Medicated Chewing Gum Delivery Systems Development. *European Journal of Pharmaceutical and Medical Research*, 2025; 12(4): 567-589.
149. Alburyhi MM, Saif AA, Noman MA, Al-Ghorafi MA. Comparative Study of Certain Commercially Available Brands of Paracetamol Tablets in Sana'a City, Yemen. *European Journal of Pharmaceutical and Medical Research*, 2018; 5(12): 36-42.
150. Alburyhi MM, Saif AA, Noman MA, Al khawlani MA. Formulation and Evaluation of Bisoprolol Fast Dissolving Tablets. *World Journal of Pharmaceutical Research*, 2023; 12(16): 01-10.
151. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Tribulus Terrestris Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Controlling Diabetes. *World Journal of Pharmaceutical Research*, 2024; 13(7): 1264-1282.
152. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Pandanus Odoratissimus Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Hepatoprotective. *European Journal of Pharmaceutical and Medical Research*, 2024; 11(4): 06-13.
153. Alburyhi MM, Noman MA, Saif AA, Salim YA, Abdullah JH. Formulation and Evaluation of Domperidone Orodispersible Tablets. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(3): 49-68.
154. Alburyhi MM, Saif AA, Noman MA, Hamidaddin MA. Formulation and Evaluation of Clopidogrel Orodispersible Tablets. *World Journal of Pharmaceutical Research*, 2024; 13(6): 42-64.
155. Alburyhi MM, Saif AA, Noman MA, Al Khawlani MA. Bisoprolol-Excipient Compatibility Studies for Advanced Drug Delivery Systems Development. *World Journal of Pharmaceutical and Medical Research*, 2024; 10(10): 304-324.
156. Bary AA, El-Gazayerly ON, Alburyhi MM. A Pharmaceutical Study on Methocarbamol. MSc Thesis, Faculty of Pharmacy, Cairo University, 2006.
157. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Plicosepalus Acacia Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Hepatoprotective. *World Journal of Pharmaceutical Research*, 2025; 14(8): 1309-1334.
158. Saif AA, Alburyhi MM, Noman MA. Formulation and Evaluation of Ketoprofen Fast Dissolving Tablets. *International Journal of Sciences*, 2018; 7(09): 27-39.
159. Saif AA, Alburyhi MM, Noman MA, Almaktari AM. Formulation and Evaluation of Trimetazidine Hydrochloride and Clopidogrel Bisulphate Multi-unit Solid Dosage Forms. *Journal of Chemical Pharm Research*, 2014; 6(2): 421-426.
160. Noman MA, Alburyhi MM, El-Shaibany A, Alwesabi NA. Preformulation and Characterization Studies of Pandanus Odoratissimus L Extract Active Ingredient in Treatment of Nocturnal Enuresis. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(2): 1603-1620.
161. Alburyhi MM, El-Shaibany A. Formulation and Evaluation of Oral Pharmaceutical Solution of Pandanus Odoratissimus L Extract Herbal Product in Treatment of Nocturnal Enuresis. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2024; 13(1): 1840-1851.
162. Alburyhi MM, El-Shaibany A. Formulation and Evaluation of Antibacterial Orodispersible Tablets of Artemisia Arborescence Extract Herbal Product. *European Journal of Pharmaceutical and Medical Research*, 2024; 11(2): 409-417.
163. Saif AA, Alburyhi MM, Noman MA. Evaluation of Vitamin and Mineral Tablets and Capsules in Yemen Market. *Journal of Chemical Pharma Research*, 2013; 5(9): 15-26.

164. Alburyhi MM, El-Shaibany A. Formulation, Development and Evaluation of Acalypha Fruticosa Extract Tablets Delivery System as an Advanced Phytotherapy Approach for Controlling Diabetes. *World Journal of Pharmaceutical Research*, 2024; 13(8): 1073-1091.
165. Noman MA, Alburyhi MM, El-Shaibany A, Alwesabi NA. Formulation and Evaluation of Pandanus Odoratissimus L Extract for Treatment of Nocturnal Enuresis as Orodispersible Tablets Delivery System. *World Journal of Pharmaceutical Research*, 2024; 13(5): 56 -71.
166. Salim YA, Yahya TA, Hamidaddin MA, Alburyhi MM. An In-Vitro New Bioequivalence Study and Densitometric Method for Determination of Azithromycin Tablets of Different Brands. *Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry*, 2020; 8(4): 147-152.
167. Alburyhi MM, Saif AA, Noman MA, Yassin SH. Simvastatin-Excipient Compatibility Studies for Advanced Drug delivery Systems Development. *World Journal of Pharmaceutical Research*, 2024; 13(19): 1463-1512.
168. Garg BK, Gnanarajan G, Kothiyal P. Formulation and Evaluation of Pulsatile Drug Delivery System of Rosuvastatin Calcium Using Different Swelling Polymers. *The Pharma Innovation*, 2012; 1(7).
169. Rane AB, Gattani SG, Kadam VD, Tekade AR. Formulation and Evaluation of Press Coated Tablets for Pulsatile Drug Delivery Using Hydrophilic and Hydrophobic Polymers. *Chemical and Pharmaceutical Bulletin*, 2009; 57(11): 1213-1217.
170. Jayasree B, Sridhar Babu G, Srikanth L. Formulation and Evaluation of Press Coated Pulsatile Delivery of Flurbiprofen Tablets. *International Journal of Innovative Research in Technology*, 2021; 8(3).
171. Giri S, Mohapatra S. Formulation and InVitro Characterization of Time Release Tablets of Propranolol Hydrochloride. *Indian Journal of Pharmaceutical Sciences*, 2020; 82(2): 216-221.
172. Kumar PJ, Muzib YI, Misra G. Formulation and Evaluation of Pulsatile Drug Delivery of Lovastatin. *Research Journal of Pharmacy and Technology*, 2018; 11(7): 2797-2803.
173. Reddy NV, Kishore K, Kumar GV. Formulation and Evaluation of Enalapril Floating Pulsatile Tablets. *EPRA International Journal of Research & Development (IJRD)*, 2021; 6(11): 1-11.
174. Golla C. Design and Evaluation of Press Coated Pulsatile Delivery of Doxofylline Tablets. *Acta Scientific Pharmaceutical Sciences*, 2018; 2(11): 58-62.
175. Borgaonkar PA, Bushetti SS, Najmuddin M. Formulation and Evaluation of Pulsatile Drug Delivery System of Metoprolol Tartrate Using Core in Cup Tablet. *American Journal of Medicine and Medical Sciences*, 2012; 2(6): 114-122.
176. Adhikari C, Kulkarni GS, Swamy S. Formulation and Evaluation of Pulsatile Drug Delivery System of Salbutamol Sulfate for the Chronotherapy of Asthma. *Asian J Pharm Clin Res*, 2018; 11(9): 305-311.
177. Gupta MK, Saraf S. Formulation and Evaluation of Pulsatile Drug Delivery System of Ramipril for Controlling Morning Spate of BP. *Journal of Pharmaceutical Research*, 2018; 17(1): 2-12.
178. Rambabu S, Vallabhbhai P. Formulation and Optimization of Press-Coated Pulsatile Tablet of Felodipine by Chronopharmaceutical Approach in Treatment of Hypertension. *International Journal of Pharmacy and Pharmaceutical Research*, 2015; 4(2): 2349-7203.
179. Kumar B, Shah M, Kumar R. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome. *Cureus*, 2019; 11: e4898.
180. Shekhawat P, Pokharker V. Understanding Peroral Absorption: Regulatory Aspects and Contemporary Approaches to Tackling Solubility and Permeability Hurdles. *Acta Pharma Sin B*, 2017; 7: 260-280.
181. Rohini P, Pavani A, Raja Reddy R. Formulation and Evaluation of Orally Disintegrating Tablets of Rosuvastatin. *Int J Pharm Sci Rev Res*, 2014; 24: 209-214.
182. Karaźniewicz-Łada M, Bąba K, Dolatowski F. The Polymorphism of Statins and its Effect on Their Physicochemical Properties. *Polim Med*, 2018; 48: 77-82.
183. Tannebaum EJ. Oral Solid Dosage Facilities. in: *Good Design Practices for GMP Pharmaceutical Facilities*, Ed.; New York, NY, USA, 2005; 2.
184. Rameshbhai M, Manikkath J, Sivkumar K. Long Circulating PEGylated-Chitosan Nanoparticles of Rosuvastatin Calcium: Development and InVitro and In Vivo Evaluations. *Int J Biol Macromol*, 2018; 107: 2190-2200.
185. Creekmore JR, Wiggins NA. Pharmaceutical Composition Comprising an HMG COA Reductase Inhibitor. European Patent Office. Patent No. EP1223918, 2002.
186. Singh J, Walia M, Harikumar S. Formulation and Evaluation of Fast Dissolving Tablets of Rosuvastatin: Research Article. *Journal of Drug Delivery & Therapeutics. JDDT*, 2014; 4: 173-81.
187. Schwartz JB. Scale Up of the Compaction and Tableting process. in *Pharmaceutical Process Scale Up*; Marcel Dekker Inc.: New York, NY, USA, 2002.
188. Zhou C, Gao W, Lu G. Preparation, Characterization, and InVitro Release of Microparticles Based on Dextran-Rosuvastatin Conjugate. *Carbohydrate Polymers*, 2013; 96: 156-162.
189. Hariharan M, Gupta VK. A Novel Compression Coated Tablet Dosage Form. *Pharm Tech*, 2001; 14-19.
190. Akbari BV, Valaki BP, Maradiya VH Akbari AK, Vidyasagar G. Development and Evaluation of Oral Dispersible Tablets of Rosuvastatin Calcium-HP-β-

CD Inclusion Complex by Using Different Superdisintegrants. Int J Pharm Technol, 2011; 3(1): 1842-1859.